Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Top Cited Papers
Open Access
- 17 February 2016
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 10501
Abstract
Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. In this study, to elucidate mechanisms of adaptive resistance, we analyse the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma. In tumours progressing following response to anti-PD-1 therapy, we observe upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3), in PD-1 antibody bound T cells and demonstrate a survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade. Two patients who developed adaptive resistance to anti-PD-1 treatment also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure. These data suggest that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.Keywords
This publication has 37 references indexed in Scilit:
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsJournal of Clinical Investigation, 2014
- Immune Modulation in Cancer with AntibodiesAnnual Review of Medicine, 2014
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008